Conventional treatment (n = 8) | Adjunct RBC exchange (n = 5) | ||
---|---|---|---|
Median Age in years (range) | 43 (1–64) | 54 (30–71) | |
Sex (Male / female) | 7 / 1 | 4 / 1 | |
Median days on ICU (range) | 6.5 (2–45) | 7 (2–81) | |
Ethnicity | Caucasian | 5 | 4 |
African | 2 | - | |
Middle East | 1 | 1 | |
Area of Infection (n) | Africa | 7 | 5 |
Other | 1 (Nicaragua) | - | |
Prophylaxis (n) | Yes | - | - |
No | 5 | 4 | |
Not determined | 3 | 1 | |
Cerebral malaria (n) | 6 (75 %) | 3 (60 %) | |
Parasitaemia >10 % (n) | 6 (75 %) | 5 (100 %) | |
Mechanical ventilation (n) | 5 (63 %) | 2 (40 %) | |
Acute renal failure 1 (n) | 4 (50 %) | 2 (40 %) | |
Norepinephrine demand (n) | 4 (50 %) | 4 (80 %) | |
Baseline laboratory parameters (median, range) | Haemoglobin (g/dl) | 11.45 (4.9-16.1) | 8.3 (5.7-12.6) |
Platelets (G/l) | 28.5 (14–50) | 46 (15–82) | |
Lactate (mmol/l) | 3.1 (2.2-5.02) | 5.1 (2.3-12.9) | |
LDH (U/l) | 779 (278–1392) | 692.5 (340–1848) | |
Blood glucose (mg/dl) | 123 (73–226) | 85 (82–267) | |
Median APACHE II score (range) | 17 (10–29) | 26 (16–32) | |
Median SAPS II (range) | 45 (34–93) | 61 (39–78) | |
Treatment | Quinine + clindamycin | Quinine + clindamycin3 | |
Total number of RBC exchanges (n) | 0 | 7 | |
·Patients with 1 RBC exchange | 0 | 3 | |
·Patients with 2 RBC exchanges | 0 | 2 | |
Adverse Events (moderate or sever intensity) | 4 | 4 | |
Adverse events related to RBC exchange | - | - | |
Unrelated adverse events | ARDS (n = 2) | ARDS (n = 1) | |
Septic shock (n = 1) | VAP (n = 1) | ||
Retinopathy (n = 1) | Fungal sepsis (n = 1) | ||
Increase of intracranial pressure (n = 1) | DIC (n = 1) | ||
Pneumonia (n = 2) | Death (n = 1) | ||
Delirium (n = 2) | |||
DIC (n = 2) |